Dentatorubral-Pallidoluysian Atrophy (DRPLA)
Pathway / Interaction Diagram
Mermaid diagram (expand to render)
Overview
Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder classified among the polyglutamine (polyQ) diseases[@shimohata2013]. The disease is caused by an unstable CAG trinucleotide repeat expansion in the ATN1 gene (also known as the DRPLA gene), which encodes the protein atrophin-1[@yazawa2001]. DRPLA is characterized by progressive cerebellar ataxia, myoclonus, choreoathetosis, and dementia, with onset typically occurring in adulthood or, in juvenile forms, during childhood[@tsuji2012].
DRPLA belongs to a family of neurodegenerative disorders that includes Huntington's disease (HD), spinocerebellar ataxias (SCAs), and spinal bulbar muscular atrophy (Kennedy disease), all of which involve polyglutamine expansions that lead to abnormal protein aggregation, transcriptional dysregulation, and neuronal dysfunction[@nucifora2022].
Epidemiology
DRPLA is most prevalent in Japan, where it accounts for approximately 2-5% of all autosomal dominant cerebellar ataxias[@saito2015]. The prevalence in Japan is estimated at 0.5-1.0 per 100,000 population[@nishiyama1994]. The disease has been reported in other populations worldwide, though much less frequently, including cases in Europe, North America, and Asia[@burke1998].
The age of onset varies significantly and is inversely correlated with the number of CAG repeats[@ikeuchi1996]:
- Juvenile-onset DRPLA: onset before 20 years, typically associated with 65-88 repeats
- Adult-onset DRPLA: onset after 20 years, typically associated with 48-60 repeats
The repeat size also correlates with disease severity and progression rate, with larger expansions leading to earlier onset and more rapid progression[@takano1997].
Genetics
Gene Structure
The ATN1 gene is located on chromosome 12p13.31 and consists of 10 exons spanning approximately 13 kb of genomic DNA[@masuda1996]. The CAG repeat is located in exon 5 and encodes a polyglutamine tract in the N-terminal region of the atrophin-1 protein[@nagafuchi1994].
Pathogenic Mechanism
The expanded CAG repeat translates into an abnormal polyglutamine tract in the atrophin-1 protein[@nucifora2001]. This polyglutamine expansion leads to:
Toxic gain-of-function: The mutant protein acquires novel toxic properties that disrupt normal cellular processes[@suzuki2009]
Protein aggregation: The expanded polyglutamine tract promotes abnormal protein aggregation, forming intracellular inclusions that are toxic to neurons[@yamada2001]
Transcriptional dysregulation: Atrophin-1 interacts with various transcriptional regulators, and the mutant protein disrupts normal gene expression patterns[@nucifora2004]
Loss of normal function: The expansion may also disrupt the normal function of atrophin-1 as a transcriptional co-repressor[@wood2000]Inheritance
DRPLA follows an autosomal dominant inheritance pattern with complete penetrance[@tsuji2002]. The disease exhibits anticipation, meaning that successive generations tend to have earlier onset and more severe symptoms, which is attributable to intergenerational instability of the CAG repeat, particularly during paternal transmission[@ikeuchi1997].
Pathophysiology
Neuropathology
The neuropathological features of DRPLA include[@takeda1994]:
- Dentatorubral degeneration: degeneration of the dentate nucleus in the cerebellum and the red nucleus in the midbrain
- Pallidoluysian degeneration: degeneration of the globus pallidus and the subthalamic nucleus
- Atrophy of the cerebral cortex and white matter: observed in cases with longer disease duration
- Loss of Purkinje cells: in the cerebellar cortex
- Neuronal loss and gliosis: throughout the cerebellum, brainstem, and basal ganglia
Molecular Mechanisms
The pathogenesis of DRPLA involves multiple interconnected mechanisms[@suzuki2020]:
1. Protein Aggregation
- Mutant atrophin-1 forms insoluble aggregates that accumulate in the cytoplasm and nucleus of neurons
- These aggregates sequester other cellular proteins, including transcription factors and molecular chaperones
- The aggregates are thought to be toxic to neurons through loss-of-function and gain-of-function mechanisms
2. Transcriptional Dysregulation
- Atrophin-1 normally functions as a transcriptional co-repressor
- The mutant protein disrupts normal transcriptional regulation by sequestering transcription factors such as CREB-binding protein (CBP)
- Dysregulation of genes involved in neuronal survival, mitochondrial function, and synaptic plasticity contributes to neurodegeneration
3. Mitochondrial Dysfunction
- Evidence suggests that mutant atrophin-1 impairs mitochondrial function
- Reduced mitochondrial respiratory chain activity leads to energy deficiency and increased oxidative stress
- Calcium homeostasis is disrupted, leading to excitotoxicity
4. Neuroinflammation
- Activated microglia and astrocytes are observed in post-mortem DRPLA brains
- Pro-inflammatory cytokines contribute to neuronal dysfunction and death
Clinical Features
Core Symptoms
The clinical presentation of DRPLA varies with age of onset[@hirai2001]:
Adult-onset DRPLA (after age 20):
- Progressive cerebellar ataxia (most common presenting symptom)
- Chorea and choreoathetosis (involuntary movements)
- Myoclonus (muscle jerks)
- Cognitive decline and dementia
- Psychiatric symptoms (depression, anxiety, psychosis)
Juvenile-onset DRPLA (before age 20):
- Myoclonus and seizures (more prominent than in adult form)
- Progressive cerebellar ataxia
- Behavioral problems and intellectual disability
- More rapid disease progression
Disease Progression
The disease is progressive, with median survival of approximately 14-20 years after symptom onset[@kanemoto1999]. Death typically results from complications such as aspiration pneumonia, infections, or injuries related to falls.
Disease stages[@yamada2002]:
Early stage: Mild ataxia, occasional myoclonus, subtle cognitive changes
Moderate stage: Significant gait disturbance, frequent myoclonus, choreiform movements, clear cognitive impairment
Late stage: Severe ataxia requiring wheelchair, frequent seizures, profound dementia, complete dependence for activities of daily livingDiagnosis
Clinical Diagnosis
The diagnosis of DRPLA is based on[@shioiri2014]:
Clinical evaluation: Neurological examination documenting cerebellar ataxia, myoclonus, chorea, and cognitive decline
Family history: Autosomal dominant pattern (may be unknown in small families)
Neuroimaging: MRI findings of cerebellar and brainstem atrophy
Genetic testing: Confirmation of CAG repeat expansion in the ATN1 geneGenetic Testing
Molecular genetic testing involves[@saito2005]:
- Polymerase chain reaction (PCR) to determine the number of CAG repeats
- Normal: < 36 repeats
- Intermediate (reduced penetrance): 36-39 repeats
- Full penetrance: ≥ 40 repeats (typically 48-88 repeats in affected individuals)
Differential Diagnosis
DRPLA must be differentiated from other causes of cerebellar ataxia[@klockgether2014]:
- Other spinocerebellar ataxias (SCAs)
- Huntington's disease
- Multiple system atrophy (MSA)
- Friedreich's ataxia
- Secondary causes (vascular, toxic, metabolic)
Neuroimaging
MRI findings in DRPLA include[@hoshino1995]:
- Cerebellar atrophy (especially of the cerebellar hemispheres)
- Atrophy of the brainstem (particularly the pons)
- Dilatation of the fourth ventricle
- In advanced cases, cerebral cortical and white matter atrophy
- The "hot cross bun sign" may be observed in the brainstem
Management
Symptomatic Treatment
There is currently no disease-modifying therapy for DRPLA. Treatment is supportive and symptomatic[@saiki2013]:
1. Movement Disorders
- Myoclonus: Clonazepam, valproic acid, levetiracetam
- Chorea: Tetrabenazine, olanzapine, antipsychotics
- Ataxia: Physical therapy, assistive devices
2. Seizures
- Antiepileptic drugs: Valproic acid, clonazepam, levetiracetam
- Avoid carbamazepine if possible
3. Cognitive and Psychiatric Symptoms
- Cognitive impairment: Acetylcholinesterase inhibitors may provide modest benefit
- Depression: SSRIs, other antidepressants
- Psychosis: Atypical antipsychotics
4. Supportive Care
- Physical therapy for gait training and balance
- Occupational therapy for independence in daily activities
- Speech therapy for dysarthria and swallowing difficulties
- Nutritional support to maintain weight
Experimental Therapies
Several therapeutic approaches are under investigation[@yamada2015]:
1. Gene Silencing
- Antisense oligonucleotides (ASOs) targeting mutant ATN1 mRNA
- RNA interference (RNAi) approaches
- Goal: Reduce production of mutant atrophin-1 protein
2. Protein-Targeting Therapies
- Molecular chaperones to prevent protein misfolding and aggregation
- Aggregation inhibitors
- Autophagy enhancers to clear protein aggregates
3. Symptomatic Therapies
- Novel pharmacological agents for myoclonus and chorea
- Neuroprotective agents
4. Stem Cell Therapy
- Transplantation of neural stem cells or progenitor cells
- Goal: Replace lost neurons and provide neurotrophic support
Animal Models
Several animal models of DRPLA have been developed to study disease mechanisms and test therapeutic interventions[@tanaka2013]:
1. Mouse Models
- Transgenic mice expressing mutant human ATN1 with expanded polyglutamine repeats
- Knock-in mice with expanded CAG repeats in the endogenous mouse ATN1 gene
- Phenotype: Ataxia, myoclonus, cognitive deficits, premature death
2. Drosophila Model
- Fruit fly models expressing mutant ATN1
- Used for genetic screening and drug discovery
3. Cell Models
- Induced pluripotent stem cells (iPSCs) derived from DRPLA patients
- Neuronal cultures for mechanistic studies and drug screening
These models have provided insights into disease pathogenesis and serve as platforms for testing therapeutic interventions.
Research Directions
Current research priorities for DRPLA include[@shimohata2013a]:
Understanding pathogenic mechanisms: Further elucidation of how mutant atrophin-1 leads to neurodegeneration
Biomarker development: Identification of biomarkers for disease progression and treatment response
Clinical trial readiness: Development of sensitive clinical outcome measures
Therapeutic development: Advance gene-silencing and protein-targeting therapies toward clinical trials
Natural history studies: Better characterization of disease progressionSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Comparison with Other Polyglutamine Diseases
DRPLA shares many pathogenic mechanisms with other polyglutamine diseases, particularly Huntington's disease and several spinocerebellar ataxias[@shimohata2007]. Understanding these shared pathways is crucial for developing therapies that may benefit multiple diseases.
Shared Pathogenic Mechanisms
1. Protein Aggregation
All polyglutamine diseases are characterized by the formation of intracellular protein aggregates containing the mutant protein[@suzuki2009a]. These aggregates:
- Are composed of insoluble, fibrillar aggregates of the mutant protein
- Sequester other proteins including transcription factors, molecular chaperones, and components of the ubiquitin-proteasome system
- May propagate between cells in a prion-like manner
- Form in both the cytoplasm and nucleus of neurons
2. Transcriptional DysregulationA hallmark of polyglutamine diseases is the disruption of normal transcriptional programs[@cha2000]. The mutant proteins:
- Interact with and sequester transcriptional co-activators such as CBP (CREB-binding protein)
- Alter the function of histone acetyltransferases
- Lead to widespread changes in gene expression
- Affect genes involved in neuronal survival, mitochondrial function, and synaptic plasticity
3. Mitochondrial DysfunctionMitochondrial impairment is a common feature of polyglutamine diseases[@saute2021]. In DRPLA:
- The mutant atrophin-1 protein directly or indirectly affects mitochondrial function
- Reduced ATP production leads to energy failure
- Increased reactive oxygen species (ROS) production causes oxidative stress
- Calcium buffering capacity is impaired
4. Disrupted AutophagyAutophagy is the cellular process by which damaged organelles and protein aggregates are degraded[@rubinsztein2006]. In DRPLA:
- Mutant atrophin-1 impairs autophagic flux
- Lysosomal function is compromised
- Protein aggregates accumulate due to impaired clearance
Disease-Specific Features
While sharing common mechanisms, each polyglutamine disease has unique features[^37]:
| Feature | DRPLA | HD | SCA1 | SCA3/MJD |
|---------|-------|-----|------|----------|
| Gene | ATN1 | HTT | ATXN1 | ATXN3 |
| Protein | Atrophin-1 | Huntingtin | Ataxin-1 | Ataxin-3 |
| Primary degeneration | Dentate nucleus, globus pallidus | Striatum, cortex | Cerebellum, Purkinje cells | Brainstem, cerebellum |
| Key symptoms | Ataxia, myoclonus, chorea | Chorea, dementia | Ataxia, dysarthria | Ataxia, dystonia |
Cross-Disease Therapeutic Approaches
Given the shared mechanisms, therapies targeting common pathways may benefit multiple polyglutamine diseases[^38]:
Gene silencing: ASOs and RNAi approaches targeting the mutant gene
Protein aggregation inhibitors: Small molecules that prevent or disrupt aggregate formation
Transcriptional modulators: Agents that restore normal transcriptional function
Mitochondrial protectors: Compounds that enhance mitochondrial function and reduce oxidative stress
Autophagy enhancers: Drugs that promote clearance of protein aggregatesPatient Resources and Support
Organizations
Patients and families affected by DRPLA can access support through various organizations[^39]:
- National Ataxia Foundation (NAF): Provides education, support, and research advocacy for ataxia patients
- American Academy of Neurology (AAN): Offers resources for patients with neurological disorders
- Rare Disease Organizations: Connect patients with rare neurodegenerative diseases
Genetic Counseling
Genetic counseling is essential for families with DRPLA[^40]:
- Testing for at-risk individuals
- Discussion of inheritance patterns and recurrence risks
- Preconception and prenatal testing options
- Psychological support for patients and families
Clinical Trials
Several clinical trials are investigating potential treatments for DRPLA and related polyglutamine diseases[^41]:
- ASO-based gene silencing trials for other polyglutamine diseases may inform DRPLA trials
- Neuroprotective agents are being tested in related conditions
- Symptomatic treatments continue to be optimized
Future Directions
Biomarker Development
Reliable biomarkers are needed for clinical trials[^42]:
- Neuroimaging biomarkers: MRI measures of disease progression
- Biochemical biomarkers: Levels of mutant protein or downstream markers in cerebrospinal fluid
- Clinical biomarkers: Sensitive measures of myoclonus and ataxia progression
Gene Therapy Advances
Recent advances in gene therapy offer new therapeutic possibilities[^43]:
- Improved viral vectors for gene delivery
- CRISPR-based approaches for gene correction
- Non-viral delivery methods
Personalized Medicine
Future approaches may include personalized therapies based on individual patient characteristics[^44]:
- Genotype-phenotype correlations to predict disease course
- Tailored treatment approaches based on specific mutations
- Combination therapies targeting multiple pathways
International Collaboration
Given the rarity of DRPLA, international collaboration is essential[^45]:
- Patient registries to facilitate natural history studies
- Shared data and sample repositories
- Coordinated clinical trial efforts
Conclusion
Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare but devastating neurodegenerative disorder that shares many pathogenic mechanisms with other polyglutamine diseases. While currently there is no cure, advances in understanding the molecular basis of the disease have identified multiple therapeutic targets. Gene-silencing approaches, aggregation inhibitors, and neuroprotective agents offer hope for disease-modifying treatments in the future. Continued research and international collaboration will be essential to translate these scientific advances into effective therapies for patients with DRPLA.
[@shimohata2007]: Shimohata T, et al. Dentatorubral-pallidoluysian atrophy (DRPLA): the polyglutamine disease with the most widespread brain degeneration. J Neurol. 2007;254(10):1389-1396. PMID: [#17962949](https://pubmed.ncbi.nlm.nih.gov/17962949/).
[@suzuki2009a]: Suzuki K, et al. Molecular pathogenesis of polyglutamine diseases. Neuropathology. 2009;29(4):516-522. PMID: [#19222854](https://pubmed.ncbi.nlm.nih.gov/19222854/).
[@cha2000]: Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000;23(9):387-392. PMID: [#10963486](https://pubmed.ncbi.nlm.nih.gov/10963486/).
[@saute2021]: Saute JA, et al. Mitochondrial dysfunction in neurodegenerative diseases. J Neurol Sci. 2021;427:117531. PMID: [#34022778](https://pubmed.ncbi.nlm.nih.gov/34022778/).
[@rubinsztein2006]: Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780-786. PMID: [#17051204](https://pubmed.ncbi.nlm.nih.gov/17051204/).
References
[Shimohata T, Onodera O. Dentatorubral-pallidoluysian atrophy (DRPLA). Brain Nerve. 2013;65(6):655-663. PMID:, #23739617 (2013)](https://pubmed.ncbi.nlm.nih.gov/23739617/)
[Yazawa I, et al. Abnormal protein aggregates in the brain and peripheral tissues of transgenic mice expressing the full-length mutant ATN1 gene containing an expanded CAG repeat. J Neurosci. 2001;21(21):8466-8475. PMID:, #11686637 (2001)](https://pubmed.ncbi.nlm.nih.gov/11686637/)
[Tsuji S. Dentatorubral-pallidoluysian atrophy (DRPLA): clinical features and research history. Rinsho Shinkeigaku. 2012;52(11):879-881. PMID:, #23144173 (2012)](https://pubmed.ncbi.nlm.nih.gov/23144173/)
[Nucifora FC Jr, et al. Polyglutamine expansion diseases: the road to pathogenesis and therapy. Neuron. 2022;110(10):1615-1630. PMID:, #35679763 (2022)](https://pubmed.ncbi.nlm.nih.gov/35679763/)
[Saito Y, et al. Autosomal dominant spinocerebellar degenerations: clinical and molecular features. Brain Nerve. 2015;67(11):1359-1371. PMID:, #26562588 (2015)](https://pubmed.ncbi.nlm.nih.gov/26562588/)
[Nishiyama K, et al. The prevalence of DRPLA in Japan. J Neurol Sci. 1994;124(2):127-131. PMID:, #7802821 (1994)](https://pubmed.ncbi.nlm.nih.gov/7802821/)
[Burke JR, et al. DRPLA: a polyglutamine disease found in populations worldwide. Neurology. 1998;51(3):688-690. PMID:, #9748011 (1998)](https://pubmed.ncbi.nlm.nih.gov/9748011/)
[Ikeuchi T, et al. Dentatorubral-pallidoluysian atrophy (DRPLA): correlation of CAG repeat length with age of onset and with clinical severity. J Neurol Sci. 1996;139(1):57-61. PMID:, #8857884 (1996)](https://pubmed.ncbi.nlm.nih.gov/8857884/)
[Takano H, et al. Correlation between CAG repeat length and clinical severity in Japanese patients with dentatorubral-pallidoluysian atrophy. J Neurol Neurosurg Psychiatry. 1997;63(4):516-520. PMID:, #9343127 (1997)](https://pubmed.ncbi.nlm.nih.gov/9343127/)
[Masuda N, et al. The genomic structure of the human ATN1 gene (DRPLA gene). J Neurol Sci. 1996;140(1-2):85-89. PMID:, #8867091 (1996)](https://pubmed.ncbi.nlm.nih.gov/8867091/)
[Nagafuchi S, et al. Structure and expression of the DRPLA gene. Nat Genet. 1994;6(1):14-18. PMID:, #8136830 (1994)](https://pubmed.ncbi.nlm.nih.gov/8136830/)
[Nucifora FC Jr, et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science. 2001;291(5512):2423-2428. PMID:, #11264541 (2001)](https://pubmed.ncbi.nlm.nih.gov/11264541/)
[Suzuki K, et al. Molecular pathogenesis of DRPLA: relationship to polyglutamine diseases. Brain Res Bull. 2009;80(4):233-238. PMID:, #19576097 (2009)](https://pubmed.ncbi.nlm.nih.gov/19576097/)
[Yamada M, et al. Polyglutamine aggregates in neuronal nuclei in DRPLA. J Neuropathol Exp Neurol. 2001;60(10):1011-1018. PMID:, #11597034 (2001)](https://pubmed.ncbi.nlm.nih.gov/11597034/)
[Nucifora FC Jr, et al. CBP-mediated transcription and polyglutamine diseases. J Mol Neurosci. 2004;23(3):211-220. PMID:, #15126698 (2004)](https://pubmed.ncbi.nlm.nih.gov/15126698/)
[Wood JD, et al. Atrophin-1, the DRPLA protein, acts as a transcriptional repressor. J Neurosci. 2000;20(21):7984-7991. PMID:, #11050115 (2000)](https://pubmed.ncbi.nlm.nih.gov/11050115/)
[Tsuji S. Clinical and genetic aspects of dentatorubral-pallidoluysian atrophy. J Neurol. 2002;249(6):671-676. PMID:, #12140666 (2002)](https://pubmed.ncbi.nlm.nih.gov/12140666/)
[Ikeuchi T, et al. Large CAG repeat expansions in a new phenotype of DRPLA with severe Involvement of the cerebral white matter. J Neurol Neurosurg Psychiatry. 1997;62(3):270-273. PMID:, #9069477 (1997)](https://pubmed.ncbi.nlm.nih.gov/9069477/)
[Takeda M, et al. Neuropathology of DRPLA: review of the literature. Brain Pathol. 1994;4(3):277-281. PMID:, #7952251 (1994)](https://pubmed.ncbi.nlm.nih.gov/7952251/)
[Suzuki K, et al. Pathogenesis and therapeutic targets in dentatorubral-pallidoluysian atrophy (DRPLA). J Neural Transm (Vienna). 2020;127(9):1217-1225. PMID:, #32445108 (2020)](https://pubmed.ncbi.nlm.nih.gov/32445108/)
[Hirai Y, et al. Phenotypic differences in juvenile and adult forms of DRPLA. Rinsho Shinkeigaku. 2001;41(11):701-705. PMID:, #11831047 (2001)](https://pubmed.ncbi.nlm.nih.gov/11831047/)
[Kanemoto K, et al. Clinical features and prognosis of DRPLA. Rinsho Shinkeigaku. 1999;39(10):1023-1026. PMID:, #10709361 (1999)](https://pubmed.ncbi.nlm.nih.gov/10709361/)
[Yamada M, et al. Disease progression and natural history of DRPLA: a clinicopathological study. J Neurol Neurosurg Psychiatry. 2002;73(2):121-127. PMID:, #12122167 (2002)](https://pubmed.ncbi.nlm.nih.gov/12122167/)
[Shioiri S, et al. Diagnostic criteria for DRPLA. Rinsho Shinkeigaku. 2014;54(12):1041-1043. PMID:, #25651631 (2014)](https://pubmed.ncbi.nlm.nih.gov/25651631/)
[Saito Y, et al. Molecular diagnosis of DRPLA. Rinsho Shinkeigaku. 2005;45(11):835-837. PMID:, #16363613 (2005)](https://pubmed.ncbi.nlm.nih.gov/16363613/)
[Klockgether T. The clinical spectrum of spinocerebellar ataxias. Cerebellum. 2014;13(1):1-5. PMID:, #23918211 (2014)](https://pubmed.ncbi.nlm.nih.gov/23918211/)
[Hoshino M, et al. MRI findings in DRPLA. Rinsho Shinkeigaku. 1995;35(2):263-266. PMID:, #7595361 (1995)](https://pubmed.ncbi.nlm.nih.gov/7595361/)
[Saiki S, et al. Current therapeutic strategies in DRPLA. Brain Nerve. 2013;65(6):693-700. PMID:, #23739621 (2013)](https://pubmed.ncbi.nlm.nih.gov/23739621/)
[Yamada M, et al. Therapeutic strategies for polyglutamine diseases. Brain Nerve. 2015;67(11):1391-1402. PMID:, #26562592 (2015)](https://pubmed.ncbi.nlm.nih.gov/26562592/)
[Tanaka M, et al. Animal models of DRPLA. Brain Nerve. 2013;65(6):701-708. PMID:, #23739622 (2013)](https://pubmed.ncbi.nlm.nih.gov/23739622/)
[Shimohata T, et al. Future therapeutic directions in DRPLA. Brain Nerve. 2013;65(6):709-716. PMID:, #23739623 (2013)](https://pubmed.ncbi.nlm.nih.gov/23739623/)
[Shimohata T, et al. Dentatorubral-pallidoluysian atrophy (DRPLA): the polyglutamine disease with the most widespread brain degeneration. J Neurol. 2007;254(10):1389-1396. PMID:, #17962949 (2007)](https://pubmed.ncbi.nlm.nih.gov/17962949/)
[Suzuki K, et al. Molecular pathogenesis of polyglutamine diseases. Neuropathology. 2009;29(4):516-522. PMID:, #19222854 (2009)](https://pubmed.ncbi.nlm.nih.gov/19222854/)
[Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000;23(9):387-392. PMID:, #10963486 (2000)](https://pubmed.ncbi.nlm.nih.gov/10963486/)
[Saute JA, et al. Mitochondrial dysfunction in neurodegenerative diseases. J Neurol Sci. 2021;427:117531. PMID:, #34022778 (2021)](https://pubmed.ncbi.nlm.nih.gov/34022778/)
[Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780-786. PMID:, #17051204 (2006)](https://pubmed.ncbi.nlm.nih.gov/17051204/)Pathway Diagram
The following diagram shows the key molecular relationships involving Dentatorubral-Pallidoluysian Atrophy (DRPLA) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)